Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer

The tumor‐stroma ratio (TSR) has proven to be a strong prognostic factor in breast cancer, demonstrating better survival for patients with stroma‐low tumors. Since the role of the TSR as a predictive marker for neoadjuvant chemotherapy outcome is yet unknown, this association was evaluated for HER2‐...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2021-09, Vol.149 (5), p.1181-1188
Hauptverfasser:	Hagenaars, Sophie C., Groot, Stefanie, Cohen, Danielle, Dekker, Tim J. A., Charehbili, Ayoub, Meershoek‐Klein Kranenbarg, Elma, Duijm‐de Carpentier, Marjolijn, Pijl, Hanno, Putter, Hein, Tollenaar, Rob A. E. M., Kroep, Judith R., Mesker, Wilma E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer Chemotherapy Chemotherapy, Adjuvant Clinical trials ErbB-2 protein Estrogen receptors Female Follow-Up Studies Humans Medical prognosis Medical research Middle Aged Miller‐Payne Multicenter Studies as Topic neoadjuvant Neoadjuvant Therapy - methods pathological response Prognosis Prospective Studies Randomized Controlled Trials as Topic Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Stroma Stromal Cells - drug effects Stromal Cells - pathology Tumor Immunology and Microenvironment Tumors tumor‐stroma ratio
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!